About Us
Novoviah’s aspiration is to have a Novoleukin Test System available for a wide range of antigens relevant to immune disease, therapies and vaccines, and to explore their clinical utility as diagnostics or monitoring tools.
Novoviah is committed to advancing sensitive and reliable clinical tests for antigen-specific T cells to support drug developers, researchers, clinicians and patients needing better treatments and diagnosis.
Novoviah is a biotechnology company established in 2020 to develop and supply a new best in-class antigen-specific T cell testing platform for clinical trials and to explore its broader application in clinical care.
Novoviah aims to strengthen pharmaceutical development programs, building on its founder’s expertise in T-cell monitoring in celiac disease to provide customised, ultrasensitive blood tests measuring antigen-specific T cells in a diverse range of indications.
Contact Us
Novoviah is dedicated to pioneering sensitive clinical tests for antigen-specific T cells, supporting clinical trials for drug developers and researchers. Established in 2020, Novoviah specialised in developing a cutting-edge testing platform for clinical trials and aspires to expand its usage into healthcare settings in the future. With a focus on enhancing pharmaceutical programs, Novoviah is committed to developing customised and highly precise blood tests for a variety of medical conditions associated with antigen-specific T cells.